RC-3095

Names

[ Name ]:
RC-3095

[Synonym ]:
L-Histidinamide, N-[[(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-glutaminyl-L-tryptophylalanyl-L-valylglycyl-N-[1-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbu tyl]-
N-[(3R)-2,3,4,9-Tetrahydro-1H-β-carbolin-3-ylcarbonyl]-L-glutaminyl-L-tryptophylalanyl-L-valylglycyl-N-(1-{[(2S)-1-amino-4-methyl-1-oxo-2-pentanyl]amino}-4-methyl-2-pentanyl)-L-histidinamide

Biological Activity

[Description]:

RC-3095 is a bombesin/gastrin releasing peptide receptor antagonist[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> GPCR/G Protein >> Bombesin Receptor

[References]

[1]. Konturek SJ, et al. Antagonism of receptors for bombesin, gastrin and cholecystokinin in pancreatic secretion and growth. Digestion. 1991;48(2):89-97.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
1547.9±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C₅₆H₇₉N₁₅O₉

[ Molecular Weight ]:
1106.322

[ Flash Point ]:
889.9±34.3 °C

[ Exact Mass ]:
1105.618530

[ LogP ]:
1.05

[ Vapour Pressure ]:
0.0±0.3 mmHg at 25°C

[ Index of Refraction ]:
1.610

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

Articles

The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats.

J. Pharmacol. Exp. Ther. 337(3) , 822-9, (2011)

Bombesin is a pruritogenic agent that causes intense itch-scratching activity in rodents. Bombesin has high affinity for the gastrin-releasing peptide (GRP) receptor (GRPr) and the neuromedin B (NMB) ...

Facilitation of the inhibitory transmission by gastrin-releasing peptide in the anterior cingulate cortex.

Mol. Pain 6 , 52, (2010)

Gastrin-releasing peptide (GRP) has been proposed as a peptidergic molecule for behavioral fear and itching. Immunohistochemistry and in situ hybridization studies have shown that GRP and GRP receptor...

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

J. Int. Med. Res. 40(4) , 1217-26, (2012)

Increased understanding of prostate cancer biology has led to new treatment strategies and promising new agents for treating prostate cancer, in particular peptide-based agonists and antagonists. In t...